The trademark application symphogen was filed by Symphogen A/S, a corporation established under the laws of the Kingdom of Denmark (the "Applicant"). The application was published for oppositions on August 23, 2022, and it was registered by office on November 30, 2022 without any oppositions.
The application was filed in English (French was selected as the second language).
Goods And Services
The mark was filed in class 1 with Chemicals used in industry, science and photography, including biochemical products, antibodies, in particular human, animal, monoclonal and polyclonal antibodies for in-vivo or in-vitro scientific research and development, including scientific research into diseases, in particular cancer, AIDS (Acquired Immune Deficiency Syndrome) and other infectious diseases, immune and auto-immune diseases, inflammatory diseases and cardiovascular diseases.
The mark was filed in class 5 with Pharmaceutical, veterinary and sanitary preparations, including pharmaceutical preparations based on antibodies, including human, animal, monoclonal and polyclonal antibodies and dietetic substances adapted for medical use..
The mark was filed in class 42 with Research in the field of medical science, including biological research and in particular research into antibodies, including human, animal, monoclonal and polyclonal antibodies and the development of medicines based on antibodies, including human, animal, monoclonal and polyclonal antibodies and chemical analyses, computer programming, namely computer programming for the gathering and processing of medical data in connection with medical science research, development and therapy, including research into, development of, and therapy using antibodies, including human, animal, monoclonal and polyclonal antibodies..